Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition for treating large intestinal cancer

A composition and colorectal cancer technology, applied in the chemical field, can solve problems such as unsatisfactory effects, and achieve the effect of inhibiting the growth of human colorectal cancer cells

Inactive Publication Date: 2008-10-29
RENJI HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] The object of the present invention is to provide a kind of pharmaceutical composition for treating colorectal cancer, described this kind of pharmaceutical composition for treating colorectal cancer will solve the effect of the pharmaceutical composition for treating colorectal cancer in the prior art. ideal technical questions

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for treating large intestinal cancer
  • Pharmaceutical composition for treating large intestinal cancer
  • Pharmaceutical composition for treating large intestinal cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0049] Example 1 Cell culture

[0050] The medium of SW480 cells (purchased from the Cell Resource Center of Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, SIBC) is RPMI-1640 complete culture medium (10% fetal bovine serum, 100U / ml penicillin / streptomycin), HT29 and HCT116 cells ( The medium purchased from the Cell Resource Center, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, SIBC) is McCOY'S 5A MEDIUM (Sigma, USA) complete culture medium (10% fetal bovine serum, 100U / ml penicillin / streptomycin), the three Culture conditions are 95% air, 5% CO 2 , 95% humidity, 37℃ constant temperature.

Embodiment 2

[0051] Example 2 MTT colorimetric experiment

[0052] Dilute the single cell suspension to 2×10 in complete culture medium 4 / ml~3×10 4 / ml, inoculate to 96-well culture plate at 100μl / well. After culturing for 24 hours, when the cells are in the logarithmic growth phase, discard the original culture medium and add each group of intervention drug working solutions (set the following drug intervention groups: 5-aza-dC 5μmol / L, 5-aza-dC 10μmol / L , RPM 10nmol / L, 5-aza-dC 5μmol / L+RPM 10nmol / L, 5-aza-dC 10μmol / L+RPM 10nmol / L; combined action in 5-aza-dC 5μmol / L+RPM 10nmol / L Group, the mass ratio of 5-aza-dC to RPM is 124.8:1, in the 5-aza-dC 10μmol / L+RPM 10nmol / L combined action group, the mass ratio of 5-aza-dC to RPM is 249.6:1), The control group was added with complete culture medium, 0.5% PBS, 0.5% dimethyl sulfoxide (DMSO). After continuing to incubate for 24, 48, 72, 96 hours, add 5 mg / ml MTT (methyl thiazolyl bluetetrazolium bromide, (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenytetra...

Embodiment 3

[0058] Example 3 Extraction of total cell protein

[0059] Following Example 2, 5-aza-dC 10μmol / L, RPM 10nmol / L, RPM10nmol / L+5-aza-dC 10μmol / L were treated for 48h, and then the total cell protein was extracted by RIPA lysis method. The specific steps are as follows: Cells Lysis buffer (Tris.HCl, 50mmol / L, pH 7.5; NaCl, 150mmol / L; NP-40, 1%; Sodium deoxycholate, 0.5%; SDS, 0.1%; EDTA, 1mmol / L; PMSF, 1mmol / L; Leupeptin, 2μg / ml) 100μl suspended cell cluster; vortex for 30s, stand on ice for 5min, repeat three times; centrifuge at 14000rpm 4℃ for 10min, collect the supernatant, which is the total protein.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a drug composite for curing colorectal cancer. The drug composite is composed of 5-N deoxycytidine and rapamycin. The weight proportion of the 5-N deoxycytidine and the rapamycin is 66.7:1-249.6:1. Compared with the use of the 5-N deoxycytidine and the rapamycin separately for the treatment of the colorectal cancer, the invention can obviously inhibit the growth of human colorectal cancer cells and can significantly reduce the incidence rate and tumor size of colorectal cancer in rats.

Description

Technical field: [0001] The present invention relates to the field of chemistry, in particular to a composition, especially a pharmaceutical composition for the treatment of colorectal cancer. Background technique: [0002] In the prior art, the effects of pharmaceutical compositions for the treatment of colorectal cancer are not ideal. Summary of the invention: [0003] The purpose of the present invention is to provide a pharmaceutical composition for the treatment of colorectal cancer. The pharmaceutical composition for the treatment of colorectal cancer should solve the problem of the pharmaceutical composition for the treatment of colorectal cancer in the prior art. Ideal technical question. [0004] The present invention is a pharmaceutical composition for treating colorectal cancer. The pharmaceutical composition is composed of 5-azodeoxycytidine and rapamycin. [0005] Further, the mass ratio of 5-azadeoxycytidine to rapamycin is in the range of 66.7:1 to 249.6:1. [000...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7068A61P35/00A61K31/436
Inventor 房静远张燕捷
Owner RENJI HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com